Current Oncology, Volume 14, Issue 11

Adjuvant therapy has made a significant contribution in reducing breast cancer–specific mortality. Standard chemotherapeutics and tamoxifen have been the mainstay treatment for years, but recent clinical evidence supports the use of novel small-molec...

For the upfront adjuvant therapy of postmenopausal estrogen receptor–positive breast cancer, the third-generation aromatase inhibitors (AIS) have shown a more favourable overall risk–benefit profile than has tamoxifen. Benefits of the AIS include les...

Treatment with aromatase inhibitors for postmenopausal women with breast cancer has been shown to reduce or obviate invasive procedures such as hysteroscopy or curettage associated with tamoxifeninduced endometrial abnormalities. The side effect of u...